Drug · CHEMBL571
KETOPROFEN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. KETOPROFEN. Drugs and targets, record CHEMBL571. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL571
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Actron, Alrheumat, Axorid, Fenoket 200, Jomethid xl, Ketocid 200, Ketonal, Ketotard 200 xl, Ketovail, Ketozip 200 xl, Larafen, Larafen cr, Nexcede, Orudis, Orudis 100, Orudis kt, Oruvail, Oruvail 100, Oruvail 150, Oruvail 200, Oruvail im, Powergel, Tiloket, Tiloket cr, Valket 200 retard
- ChEMBL
- Other names
(rs)-ketoprofen, 19583RP, Actron ketoprofen, Aneol, Capisten, Hydratropic acid, m-benzoyl-, IDEA-033, Iso-k, Ketoprofene, Ketoprofeno, Ketorin, NSC-758144, R.P. 19,583, R.P. 19583, RP-19583, RU-4733, Sector
- ChEMBL
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| PTGS1 | Cyclooxygenase | Cyclooxygenase inhibitor | INHIBITOR | https://conductscience.org/library/genes/5742 |
| PTGS2 | Cyclooxygenase | Cyclooxygenase inhibitor | INHIBITOR | https://conductscience.org/library/genes/5743 |
Source ChEMBL
Diseases23
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| osteoarthritis | Approval | DailyMed | 13 | 10 | https://conductscience.org/library/drugs?q=MONDO_0005178 |
| Pain | Approval | DailyMed | 15 | 8 | https://conductscience.org/library/drugs?q=HP_0012531 |
| osteoarthritis, knee | Phase 3 | ClinicalTrials.gov | 7 | 7 | https://conductscience.org/library/drugs?q=MONDO_0005416 |
| migraine disorder | Phase 3 | ClinicalTrials.gov | 4 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005277 |
| lymphedema | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0019297 |
| Arthralgia | Approval | ATC | 3 | 2 | https://conductscience.org/library/drugs?q=HP_0002829 |
| Myalgia | Approval | ATC | 3 | 2 | https://conductscience.org/library/drugs?q=HP_0003326 |
| Back pain | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0003418 |
| Knee pain | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0030839 |
| Low back pain | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0003419 |
1 to 10 of 23Source Open Targets
See all 23 diseasesTrials78
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 5 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02257970 | Lymphedema Study for Arm or Leg Lymphedema | Phase 4 | 117 | 2018-09-14 | ketoprofen | Its name | ClinicalTrials.gov |
| NCT02568644 | Ginger Capsules for the Acute Treatment of Migraine Attacks | 60 | 2020-04-07 | ketoprofen | Its name | ClinicalTrials.gov | |
| NCT02099006 | Novel Topical Therapies for the Treatment of Genital Pain | Phase 2/3 | 9 | 2016-07-15 | ketoprofen | Its name | ClinicalTrials.gov |
| NCT00716547 | Safety and Efficacy of Two Dosages of Diractin® in Osteoarthritis (OA) | Phase 3 | 1,399 | ketoprofen | Its name | ClinicalTrials.gov | |
| NCT00530387 | Multi-Centre European Photopatch Test Study | 1,000 | ketoprofen | Its name | ClinicalTrials.gov | ||
| NCT00211549 | An Effectiveness and Safety Study of IDEA-033 in Comparison to Oral Naproxen and Placebo for the Treatment of Osteoarthritis of the Knee | Phase 2 | 875 | IDEA-033 | Its name | ClinicalTrials.gov | |
| NCT00316784 | IDEA-033 Three Months Dose Finding in OA Followed by IDEA-033 Three Months Extension in OA | Phase 3 | 704 | IDEA-033 | Its name | ClinicalTrials.gov | |
| NCT00488267 | Efficacy of ThermoProfen in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee | Phase 3 | 679 | ketoprofen | Its name | ClinicalTrials.gov | |
| NCT02400047 | Dexamethasone, Can it Replace Ketoprofen in the Strategy of Intraoperative Multimodal Analgesia in Paediatric Surgery ? A Prospective Randomized Double-blinded Study. DEXA OP | Phase 3 | 580 | ketoprofen | Its name | ClinicalTrials.gov | |
| NCT00722852 | Study of Safety and Efficacy of Diractin® for the Treatment of Osteoarthritis (OA) of the Knee | Phase 3 | 555 | ketoprofen | Its name | ClinicalTrials.gov |
1 to 10 of 78
See all 78 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Extract of Ginger vs Cellulose: serious adverse events | 0 of 30 | 0 of 30 | 60 | NCT02568644 | Trial comparisons |
| Medications vs Placebo: serious adverse events | 0 of 9 | 0 of 9 | 18 | NCT02099006 | Trial comparisons |
Papers from its trials13
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL571
GET https://conductscience.org/api/drugs/v1/CHEMBL571/diseases?page=2